Related Experiment Videos
One-step, labeled-antibody assay for measuring free thyroxin. II. Performance in a multicenter trial
C P Sheehan1, N D Christofides
1Amerlite Diagnostics Ltd., Cardiff Laboratories, Whitchurch, U.K.
Clinical Chemistry
|January 1, 1992
Summary
A new radioassay for free thyroxin (FT4) shows excellent precision and accuracy. This Amerlex-MAB FT4 assay offers improved diagnostic performance compared to older methods, especially for patients with thyroid-related conditions.
Area of Science:
- Endocrinology
- Clinical Chemistry
- Immunoassay Technology
Background:
- Accurate measurement of free thyroxin (FT4) is crucial for diagnosing thyroid disorders.
- First-generation analog radioimmunoassays have limitations in specific patient populations.
Purpose of the Study:
- To evaluate the technical and diagnostic performance of the Amerlex-MAB* FT4 assay.
- To compare its performance against established radioimmunoassay methods.
Main Methods:
- Multicenter trial involving eight laboratories.
- Assessment of within-assay and between-assay precision.
- Correlation study with an analog radioimmunoassay.
- Evaluation of clinical performance in diverse patient groups.
Main Results:
- Excellent within-assay precision (CV 3.6–6.2%) and between-assay precision (CV 5.4–6.8%).
- Established euthyroid reference range for FT4: 11.3–24.3 pmol/L.
- High correlation with analog radioimmunoassay (r = 0.96).
- Superior clinical performance in nonthyroidal illness and binding-protein abnormalities.
Conclusions:
- The Amerlex-MAB* FT4 assay demonstrates robust technical performance.
- This assay provides reliable FT4 measurements and improved clinical utility.
- It represents an advancement over previous radioimmunoassay methods for FT4 determination.